Actively Recruiting
Randomized Controlled Trial of YN001 to Evaluate Safety and Efficacy in Men With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
Led by Beijing Inno Medicine Co., Ltd. · Updated on 2026-09-22
40
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in male patients aged 18 to 75 with atherosclerotic cardiovascular and cerebrovascular diseases and mild to moderate erectile dysfunction. The study aims to understand how YN001 might affect erectile function and vascular health in these patients. Participants are assigned to one of two groups one receiving YN001 20 mg plus 5% glucose injection once weekly, and the other receiving a placebo 5% glucose injection once weekly. Treatments are administered for 12 weeks. The trial uses a parallel study model with quadruple masking to compare the effects of the active drug versus placebo. During the study, participants will be evaluated through questionnaires assessing erectile function and undergo peripheral ultrasound to measure carotid artery thickness at baseline and after 12 weeks. Researchers will monitor adverse events for up to 16 weeks. The main outcomes measured include changes in erectile function scores and carotid artery intima-media thickness, with the trial expected to complete by December 2026.
CONDITIONS
Brief Title
Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
Research Team
J
Jean Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here